Inventiva
Yahoo Finance • 2 days ago
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up to €348 million2, foll... Full story
Yahoo Finance • 2 days ago
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités
Trésorerie et équivalents de trésorerie à 122,1 millions d’euros et dépôts à court terme1 à 24,6 millions d’euros au 30 juin 2025Produit brut de 115,6 millions d’euros reçu au titre de la deuxième tranche du financement structuré pouvant a... Full story
Yahoo Finance • 6 days ago
Inventiva to Host Analyst and Investor Event on October 8, 2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key tr... Full story
Yahoo Finance • 6 days ago
Inventiva organise un événement analystes et investisseurs le 8 octobre 2025
Le programme inclura une mise à jour sur son médicament candidat, lanifibranor, en amont des résultats principaux de l’étude de Phase 3 NATiV3 attendus au second semestre 2026 Trois experts internationaux de renom et un représentant des pa... Full story
Yahoo Finance • 11 days ago
3 out of 5 companies miss EPS estimates this week: Earnings Scorecard
[Data analytics dashboard display. Business and financial investment. HUD infographic of financial. Information reports of business strategy for investment. 3d rendering] KanawatTH/iStock via Getty Images Wall Street's major averages cl... Full story
Yahoo Finance • 26 days ago
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies... Full story
Yahoo Finance • 26 days ago
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre
Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l... Full story
Yahoo Finance • last month
Piper Sandler initiates Inventiva stock with Overweight rating on MASH potential
Investing.com - Piper Sandler initiated coverage on Inventiva SA (NASDAQ:IVA), currently valued at $730 million, with an Overweight rating and a $26.00 price target on Wednesday. The stock has shown impressive momentum, gaining over 88% in... Full story
Yahoo Finance • 3 months ago
Inventiva appoints new R&D president and regulatory affairs executive
PARIS - French biopharmaceutical company Inventiva (Euronext Paris and Nasdaq:IVA), currently valued at $456 million and maintaining impressive gross profit margins of 90%, announced Wednesday the appointment of Jason Campagna as President... Full story
Yahoo Finance • 2 years ago
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
INVENTIVA The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor... Full story
Yahoo Finance • 2 years ago
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
INVENTIVA Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fat... Full story
Yahoo Finance • 3 years ago
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
INVENTIVA The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic non-alcoholic steatohepati... Full story
Yahoo Finance • 3 years ago
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank
INVENTIVA Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program for €9.3 million and new State-backed bank financing for €5.3 million In accordance with the terms of the credit facility announc... Full story
Yahoo Finance • 3 years ago
Inventiva announces participation at several investors conferences in May and June 2022
INVENTIVA Daix (France), Long Island City (New York, United States), May 23, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule t... Full story
Yahoo Finance • 3 years ago
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
INVENTIVA Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for th... Full story
